Induction of tumor-specific IFN-γ T cell responses, and reductions of peripheral Tregs and serum IL-10 observed in 4 out of the 5 immunized patients2 out 5 immunized patients achieved prolonged progression-free survival of over 2 years. This evidence concerns the gene IL10 and neoplasm.